CannBioRx Life Sciences C...
(ATNFW)
undefined
undefined%
At close: undefined
0.01
0.00%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.
The company was founded by Marc Feldmann, Lawrence J.
Steinman, and Jonathan B.
Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
CannBioRx Life Sciences Corp.
| Country | United States |
| IPO Date | n/a |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Sir Marc Feldmann Ph.D. |
Contact Details
Address: Building 4 Palo Alto, United States | |
| Website | http://www.180lifesciences.com |
Stock Details
| Ticker Symbol | ATNFW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | n/a |
| ISIN Number | US68236V1127 |
| Employer ID | 81-3832378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Director |
| Jason Assad | Director of IR |
| Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder & Chairman of Clinical Advisory Board |
| Sir Marc Feldmann Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 3 | Filing |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 15, 2024 | S-1 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | ARS | Filing |
| Nov 12, 2024 | DEFA14A | Filing |
| Nov 12, 2024 | DEF 14A | Filing |
| Oct 31, 2024 | 8-K | Current Report |